Lab Introduces Self-Collected HPV Test to Enhance Privacy and Access
The new testing option detects 14 high-risk HPV strains without requiring pelvic examination, targeting patients 30 and older with no previous abnormal screenings.
The new testing option detects 14 high-risk HPV strains without requiring pelvic examination, targeting patients 30 and older with no previous abnormal screenings.
A new method for HPV self-testing stratifies women into three risk groups, enhancing cervical cancer screening and follow-up care.
BD is shipping its FDA-approved HPV self-collection kits to healthcare facilities, offering an accessible cervical cancer screening option.
che received FDA approval for its HPV self-collection solution, allowing individuals to collect their own samples.
Read MoreAn at-home cervical cancer screening device received Breakthrough Device status to help increase testing access for people in need.
Read MoreResearchers developed a urine-based test utilizing whole genome sequencing to detect DNA fragments released by head and neck tumors.
Read MoreThe research highlighted factors influencing cervical cancer screening and highlighted the need for interventions to increase screening.
Read MoreThe TTMV-HPV DNA blood test provides a non-invasive method for detecting HPV-driven cancers before there is clinical evidence of disease.
Read MoreThe ASCCP recognized dual-stain biomarkers as an important tech to determine if an HPV infection is transforming into cervical pre-cancer.
Read MoreNaveris Launched an initiative aimed to expand the applications of its circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test.
Read MoreBD partnered with Camtech Health to advance cervical cancer screening by offering women in Singapore the option to self-collect a sample.
Read MoreIn BD’s newest global survey, women reported self-collection would motivate them to have regular cervical cancer screening.
Read MoreResearchers discovered that lymphatic fluid from surgical drains could inform precise treatments for patients with head and neck cancer.
Read MoreRoche announced the U.S. FDA approved the cobas HPV test for use on its next-generation cobas 5800 molecular instrument.
Read MoreAbbott received FDA approval for its molecular HPV screening solution for its Alinity m family of diagnostic assays.
Read MorePhysically disabled women may encounter barriers to reproductive health care and a lack of timely access to cervical cancer screening.
Read MoreTwo liquid biopsy tests that look for HPV in blood identified patients with a high risk of cervical cancer recurrence after chemoradiation.
Read MoreResearchers developed an electrochemical DNA biosensor which effectively detects HPV-16 and HPV-18, and can diagnose cervical cancer early.
Read More